RecruitingPhase 2

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer

China37 participantsStarted 2025-08-14

Plain-language summary

This is an exploratory and prospective study, with the research subjects being patients with initially untreated and unresectable biliary tract tumors. The efficacy and safety of the treatment regimen consisting of Adebrelimab monoclonal antibody combined with targeted therapy and systemic chemotherapy were investigated.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L;
✓. Platelet count ≥ 75 × 10\^9/L;
✓. Hemoglobin ≥ 90 g/L;
✓. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN);
✓. Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 2.5 x ULN;
✓. Albumin ≥ 3 g/dL
✓. Creatinine ≤ 1.5 x ULN 9. Patients can understand and sign the informed consent form to participate in the trial study; good compliance.

What they're measuring

ORR

Timeframe: At the end of Cycle 6 and 10 (each cycle is 21 days)

Trial details

NCT IDNCT07135544

SponsorYongjun Chen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06-30

Contact for this trial

Yongjun Chen Yongjun Chen

027-83662379 yjchen@tjh.tjmu.edu.cn

View on ClinicalTrials.gov More Biliary Tract Cancer trials